Cancer Type: Breast

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201502063

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Loperamide

201503010

A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

201604023

PRAGMATIC PHASE III RANDOMIZED TRIAL OF PROTON VS. PHOTON THERAPY FOR PATIENTS WITH NON-METASTATIC BREAST CANCER RECEIVING COMPREHENSIVE NODAL RADIATION: A RADIOTHERAPY COMPARATIVE EFFECTIVENESS (RADCOMP) CONSORTIUM TRIAL

201607134

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

201612071

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

201701042

A Phase II Open-Label,Randomized Study of PARP inhibition (olaparib) Either Alone or in Combination with Anti-PD-LI Therapy (atezolizumab;MPDL3280A) in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)

201811109

A PHASE 3, MULTICENTER, RANDOMIZED,OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF DS-8201A, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS TREATMENT OF INVESTIGATOR’S CHOICE FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PRETREATED WITH PRIOR STANDARD OF CARE HER2 THERAPIES,INCLUDING T-DM1

201902108

A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer

201904141

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

201905076

An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2-Breast Cancer with an ESR1 Mutation